#United States #CTCL #LYMPHIR #Citius Oncology #Cransford, N.J.

Citius Oncology and LYMPHIR: Enhancing Patient Quality of Life

Citius Oncology, Inc. recently showcased encouraging findings regarding the quality of life (QoL) of patients undergoing treatment with LYMPHIR® (denileukin diftitox-cxdl) for relapsed or refractory cutaneous T-cell lymphoma (CTCL) at the prestigious European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting in Berlin, held from October 8 to 10. This annual congress serves as a vital platform for sharing the latest advancements in cutaneous lymphoma treatment and research.

Importance of Quality of Life in CTCL Treatment

As noted by Citius Oncology's Chairman and CEO Leonard Mazur, both clinical effectiveness and quality of life are integral to patient care in CTCL management. Treatment must address not only the cancer itself but also the debilitating symptoms that accompany this type of lymphoma, such as itchy and painful skin lesions.

The presentation delivered by Dr. Christiane Querfeld from City of Hope highlighted key results from pivotal Study 302 (NCT01871727), which assessed the health-related quality of life for adult patients participating in the trial. Study 302, a multicenter, open-label trial, notably supported the FDA approval of LYMPHIR, showing it to be a valuable option for patients with CTCL who had not responded favorably to prior treatments.

Study Findings and Patient Outcomes

In this study, patients who responded to LYMPHIR reported sustained improvements in various QoL metrics, specifically those relating to skin health. Assessment tools used included the Skindex-29, a disease-specific instrument, and the Functional Assessment of Cancer Therapy – General (FACT-G). Obtaining both functional and symptomatic data allows for a comprehensive view of the treatment's impact on patients' everyday lives.

Among the participants who responded positively to LYMPHIR treatment, substantial changes were noted in their Skindex-29 Total Score, indicating diminished skin-related symptoms. In contrast, non-responders showed minimal to no meaningful changes in their QoL metrics. On average, responders experienced an improvement of between 5.38 to 13.69 points in their Skindex-29 assessments. This demonstrates the potential of LYMPHIR not only to combat cancer cells but also to significantly enhance the overall well-being of CTCL patients.

Moreover, the FACT-G Total Score indicated that responders experienced a positive change of 3.21 points at the end of treatment, while non-responders reported a decline in quality of life by 2.28 points. These findings highlight the therapy's dual benefit in providing clinical efficacy as well as improved patient satisfaction and comfort during therapy.

The reduction of itching—a common and distressing symptom—was also emphasized, with nearly one-third of patients who were heavily pretreated reporting marked relief. Such results underscore the necessity for continued prioritization of patient comfort in treatment choices.

Future Directions for Quality of Life in CTCL

Citius Oncology recognizes that comprehensive treatment involves ongoing support and quality of life programs. To further this goal, the company is collaborating with the Cutaneous Lymphoma Foundation to host the inaugural Quality of Life Workshop in November 2026. This initiative aims to unify patients, healthcare professionals, and researchers in standardizing how QoL is evaluated and incorporated into the treatment of cutaneous lymphoma.

Conclusion

As Citius Oncology continues to advance its efforts in oncology, the promising data presented at the EORTC-CLTG meeting signifies an important step forward in the treatment of CTCL. By focusing on both clinical outcomes and quality of life measures, Citius Oncology illustrates its commitment to addressing the comprehensive needs of patients suffering from CTCL. For more details about LYMPHIR and other initiatives, visit Citius Oncology’s official website.